Although conventional anti-VEGF therapy has achieved favorable results in controlling RVO-associated macular edema, it still leaves a therapeutic gap in addressing Ang-2–mediated vascular instability and chronic inflammation. The gene discussed is ANGPT2; the disease is macular retinal edema.